[Botulinium toxin and idiopathic overactive bladder: Multicentric contempory management in Bourgogne]

Area of Science:

• Urology
• Urogynecology

Background:

• OnabotulinumtoxinA (Botox®) has been a therapeutic option for idiopathic overactive bladder since 2014.
• It is primarily used as a second-line treatment following other therapies.

Purpose of the Study:

• To evaluate the current surgical practices for OnabotulinumtoxinA (BoNTA) in treating idiopathic overactive bladder.
• To assess the heterogeneity in diagnostic, surgical, and outcome evaluation methods.

Main Methods:

• Data were collected from urogynecology centers on patients treated with BoNTA.
• Information gathered included patient symptoms, prior treatments, paraclinical evaluations, surgical details, and follow-up characteristics.

Main Results:

• Ninety-seven patients from six centers were identified, with 70% receiving injections within marketing authorization guidelines.
• BoNTA was a second-line treatment in 69% of cases, often after failed neuromodulation.
• Urodynamic evaluation was performed in 91% of patients, with post-void residual volume assessment in 59% during follow-up.

Conclusions:

• BoNTA injections for idiopathic overactive bladder are predominantly used after failure of tibial or sacral neuromodulation.
• Significant heterogeneity exists in diagnostic, surgical, and outcome evaluation practices.
• There is a clear need for greater standardization in the application of BoNTA for this indication.